Sunday , 8 November 2026
Home News 26,764 CIVIL SERVANTS TO BENEFIT FROM 2023-2024 PROMOTION EXERCISE IN OGUN.
NewsOpportunities

26,764 CIVIL SERVANTS TO BENEFIT FROM 2023-2024 PROMOTION EXERCISE IN OGUN.

Ogun State Governor, Prince Dapọ Abiodun, has approved the 2023 and 2024 promotion exercises for eligible civil servants in the state. This move demonstrates his commitment to enhancing the welfare, career growth, and development of public servants in Ogun State.
According to the Head of Service, Mr. Kehinde Onasanya, the promotion exercises will include upgrading and transfers, benefiting 26,764 (Twenty-six thousand, seven hundred and sixty four) civil servants across various cadres and ministries. The assessment method will consist solely of oral interviews.
Governor Dapo Abiodun
Mr. Kehinde Onasanya
Additionally, Governor Abiodun has approved the December 2024 edition of the Combined Confirmation/Promotion Tests and Compulsory Public Service Examinations. These exams aim to facilitate career progression for eligible officers in the junior and senior cadres.
The State Government remains committed to prioritizing workers’ welfare as part of its “Building Our Future Together” agenda. The Head of Service expressed gratitude to Governor Abiodun for his worker-friendly policies, which have significantly enhanced the well-being and career growth of workers

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

China Says It Takes Mbappé’s Apology Seriously After Mao Comment

  China has reacted to Kylian Mbappé’s apology over his comments about...

FG: Workers To Get N70,000 Monthly Transport Support From November

Federal workers will begin to receive a N70,000 monthly transport support from...

Tinubu seeks fresh $20.5bn, €1.04bn foreign loans to fund infrastructure

  In a bid to close Nigeria’s infrastructure financing gap, President Bola...

DR Congo Launches Ebola Vaccine Trial Amid Rising Outbreak

  The Democratic Republic of Congo has launched the first clinical trial...